BRCA1 and neoplasm: This also predicts that BRCA1/2 mutations should be early ‘founder' mutations in cancer, which is supported by a few BRCA1 cases in multiregion tumour sequencing.50, 51 The relative contribution of the increased SNV rates and the indel/rearrangement phenotype to the mutator function remains unknown.